Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
Recruiting · NCT06963346 · Registry updated 2026-07-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-07-30 | NCT06963346 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | United States | 523 |